Sigyn Therapeutics explores NASDAQ merger, establishes clinical pathway
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Sigyn Therapeutics Issues Shareholder Update Highlighting the Advancement of CardioDialysis(TM) and New Corporate Initiatives
January 15, 2026 11:01 AM ESTSAN DIEGO, CA - January 15, 2026 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), a developer of dialysis-like therapies to address cardiovascular disease and cancer, today released the following shareholder update authored by Chief Executive Officer, Jim Joyce.
Dear Shareholders and Interested Parties,
Cardiovascular disease is the #1 cause of death worldwide. The primary aim of treatment is to reduce major adverse cardiovascular events (MACE).
The leading class of drugs to treat cardiovascular disease are statins, which reduce the incidence of MACE by approximately 25%. In contrast, blood purification therapies (lipoprotein apheresis) can... More
